Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.

Mazzoccoli L, Robaina MC, Apa AG, Bonamino M, Pinto LW, Queiroga E, Bacchi CE, Klumb CE.

J Cancer Res Clin Oncol. 2018 Mar;144(3):483-497. doi: 10.1007/s00432-017-2575-3. Epub 2018 Jan 9.

PMID:
29318382
2.

miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis.

Robaina MC, Faccion RS, Mazzoccoli L, Rezende LM, Queiroga E, Bacchi CE, Thomas-Tikhonenko A, Klumb CE.

Ann Hematol. 2016 May;95(6):881-91. doi: 10.1007/s00277-016-2653-7. Epub 2016 Apr 5.

PMID:
27044389
3.

Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.

Ferreira AC, de-Freitas-Junior JC, Morgado-Díaz JA, Ridley AJ, Klumb CE.

J Leukoc Biol. 2016 Apr;99(4):569-78. doi: 10.1189/jlb.2A0415-162R. Epub 2015 Nov 11.

PMID:
26561567
4.

NFAT2 Isoforms Differentially Regulate Gene Expression, Cell Death, and Transformation through Alternative N-Terminal Domains.

Lucena PI, Faget DV, Pachulec E, Robaina MC, Klumb CE, Robbs BK, Viola JP.

Mol Cell Biol. 2015 Oct 19;36(1):119-31. doi: 10.1128/MCB.00501-15. Print 2016 Jan 1.

5.

An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation.

Maia RC, Bonamino MH, Robaina MC, Amaral N, Bonecker S, Zalcberg IR, Klumb CE.

Blood Cells Mol Dis. 2015 Dec;55(4):347-50. doi: 10.1016/j.bcmd.2015.07.013. Epub 2015 Jul 21.

PMID:
26460258
6.

Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.

Nakamura KD, Tilli TM, Wanderley JL, Palumbo A Jr, Mattos RM, Ferreira AC, Klumb CE, Nasciutti LE, Gimba ER.

Tumour Biol. 2016 Feb;37(2):2655-63. doi: 10.1007/s13277-015-4095-6. Epub 2015 Sep 24.

PMID:
26404131
7.

Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.

Robaina MC, Mazzoccoli L, Arruda VO, Reis FR, Apa AG, de Rezende LM, Klumb CE.

Exp Mol Pathol. 2015 Apr;98(2):200-7. doi: 10.1016/j.yexmp.2015.03.006. Epub 2015 Mar 4.

PMID:
25746661
8.

Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications.

Robaina MC, Faccion RS, Arruda VO, de Rezende LM, Vasconcelos GM, Apa AG, Bacchi CE, Klumb CE.

Leuk Res. 2015 Feb;39(2):248-56. doi: 10.1016/j.leukres.2014.11.023. Epub 2014 Dec 9.

PMID:
25542698
9.

Rosai-Dorfman disease: a report of eight cases in a tertiary care center and a review of the literature.

Maia RC, de Meis E, Romano S, Dobbin JA, Klumb CE.

Braz J Med Biol Res. 2015 Jan;48(1):6-12. Epub 2014 Oct 10.

10.

Rosai-Dorfman disease: a report of eight cases in a tertiary care center and a review of the literature.

Maia RC, de Meis E, Romano S, Dobbin JA, Klumb CE.

Braz J Med Biol Res. 2014 Oct 10;0:0. [Epub ahead of print]

11.

Langerhans cell histiocytosis: differences and similarities in long-term outcome of paediatric and adult patients at a single institutional centre.

Maia RC, de Rezende LM, Robaina M, Apa A, Klumb CE.

Hematology. 2015 Mar;20(2):83-92. doi: 10.1179/1607845414Y.0000000173. Epub 2014 May 29.

PMID:
24875166
12.

Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.

Ferreira AC, Robaina MC, Rezende LM, Severino P, Klumb CE.

Ann Hematol. 2014 Jun;93(6):983-93. doi: 10.1007/s00277-014-2021-4. Epub 2014 Feb 28.

PMID:
24577510
13.

A step towards the cure of Burkitt's lymphoma in developing countries.

Klumb CE.

Rev Bras Hematol Hemoter. 2012;34(5):332-3. doi: 10.5581/1516-8484.20120087. No abstract available.

14.

Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma.

Minnicelli C, Barros MH, Klumb CE, Romano SO, Zalcberg IR, Hassan R.

PLoS One. 2012;7(9):e46005. doi: 10.1371/journal.pone.0046005. Epub 2012 Sep 27.

15.

Lymphoma subtype incidence rates in children and adolescents: first report from Brazil.

Ferreira JM, Klumb CE, de Souza Reis R, de Oliveira Santos M, Oliveira JF, de Camargo B, Pombo-de-Oliveira MS.

Cancer Epidemiol. 2012 Aug;36(4):e221-6. doi: 10.1016/j.canep.2012.03.006. Epub 2012 May 1.

16.

Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.

Dos Santos Ferreira AC, Fernandes RA, Kwee JK, Klumb CE.

J Cancer Res Clin Oncol. 2012 Feb;138(2):317-25. doi: 10.1007/s00432-011-1093-y. Epub 2011 Dec 1.

PMID:
22131152
17.

Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.

Vasconcelos FC, Silva KL, Souza PS, Silva LF, Moellmann-Coelho A, Klumb CE, Maia RC.

Cytometry B Clin Cytom. 2011 May;80(3):158-66. doi: 10.1002/cyto.b.20580. Epub 2010 Dec 2.

18.

Pediatric lymphomas in Brazil.

Gualco G, Klumb CE, Barber GN, Weiss LM, Bacchi CE.

Clinics (Sao Paulo). 2010;65(12):1267-77.

19.

Circulating cell-free and Epstein-Barr virus DNA in pediatric B-non-Hodgkin lymphomas.

Machado AS, Da Silva Robaina MC, Magalhães De Rezende LM, Apa AG, Amoêdo ND, Bacchi CE, Klumb CE.

Leuk Lymphoma. 2010 Jun;51(6):1020-7. doi: 10.3109/10428191003746331.

PMID:
20470219
20.

p53 flow cytometry evaluation in leukemias: correlation to factors affecting clinical outcome.

Cavalcanti GB Jr, Scheiner MA, Simões Magluta EP, Vasconcelos FC, Klumb CE, Maia RC.

Cytometry B Clin Cytom. 2010 Jul;78(4):253-9. doi: 10.1002/cyto.b.20514.

Supplemental Content

Loading ...
Support Center